At the news
? BULLISHIMPACT 8/10 8-K filed Feb 25, 2026 at 16:03 ET
Mirum Pharmaceuticals reported strong 2025 financial results with $521.3 million in net product sales, representing 55% year-over-year growth. The company raised its 2026 guidance to $630-$650 million in global net product sales and highlighted four upcoming clinical catalysts, including topline data for volixibat in PSC expected in Q2 2026.
- 2025 net product sales of $521.3 million, up 55% YoY from $336.4 million in 2024
- 2026 guidance raised to $630-$650 million in global net product sales
- LIVMARLI net sales reached $360.0 million in 2025, up 69% YoY
- Bile Acid Medicines net sales reached $161.3 million in 2025, up 31% YoY
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access